Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

about

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

Item

http://www.wikidata.org/entity/Q39375290

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

@en

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

@nl

type

Item

label

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

@en

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

@nl

prefLabel

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

@en

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.

@nl

P1476

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia

@en

P2093

Guang Yang

http://www.w3.org/2001/XMLSchema#string

Steven P Treon

http://www.w3.org/2001/XMLSchema#string

P2860

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Immunophenotypic analysis of Waldenstrom's macroglobulinemia

Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals

Oncogenically active MYD88 mutations in human lymphoma

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma

P304

739-744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1343661

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Castillo

Zachary Hunter

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28617062

http://www.w3.org/2001/XMLSchema#string